ZERO National Symposium 2022 - Day 1 Presentations

07 Feb 2023

The Zero Childhood Cancer Symposium 2022 held in Sydney provided a unique experience for international and national leading experts in cancer precision medicine to explore and showcase their cutting-edge progress made in the direction of curing childhood cancer through explorative, detailed, and precise developments.  

Experts from a variety of backgrounds and uniting with the goal of progressing pediatric cancer developments, explored their key reports ranging in topics such as:

  • cancer biology and clinical translation  
  • genetics, genomics and cancer predisposition  
  • bioethics and psychosocial research 
  • functional biology and preclinical modelling 
  • learning from the lived experience - parent and consumer perspectives. 

The hybrid event held at the NSW Teachers Federation Conference center with close to 200 of the world’s researchers, clinicians and health professionals attending online and in-person, span across two days and left an audience with a message that the facilities for developing a world with all children being free from cancer is well on its way.

Below are some of the research presentations that were held on the first day of the symposium 2022. 

Dr Jinghui Zhang - Utility of Whole Genome Sequencing in Clinical Profiling of Pediatric Cancer

Dr Patrick Connerty - A comparison of paediatric acute myeloid leukaemia engraftment characteristics between MISTRG and NRG-S mouse strains 

Dr Jason Cain - Targeting functional pathway dependencies in childhood and adolescent Osteosarcoma

Ihara Shazia Adjumain - An integrative genomics approach identifies MCL-1 as a therapeutic target in paediatric high-grade gliomas (pHGGs) 

Professor Hamish Scott - Proven and potential mechanisms of different phenotypes and ages of onset blood cancer predisposition genes

Sarah Parackal - Identification of Therapeutically Sensitive Molecular Dependencies in Diffuse Intrinsic Pontine Glioma

Dr Georgina Barnabas - Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. 

Anastasia Glushko, Lucy Jones, Sophy Athan, Sheila Patel Group Seminar – Consumer Advocates Group Discussion 

Since its establishment in 2017, ZERO has focused on identifying new treatment options for children with high-risk cancers – those with less than 30% chance of survival. Now, the revolutionary program will be expanded so that by the end of 2023, all children and young people up to the age of 21 years in Australia who are diagnosed with cancer will have access to precision medicine through the ZERO program. 

Find out more at